Showing results (1-10 of 146) with videos related to
Sort By:
Pageof 15
Leukemia & Lymphoma|July 15, 2021
Glofitamab CD20-TCB bispecific antibodyAdrian Minson, Michael DickinsonLeukemia & Lymphoma|December 17, 2021
A PET in a time of need: toward early PET-adapted therapy in DLBCL in first relapseAdrian Minson, Michael Hofman, Michael DickinsonCancers|March 10, 2022
Targeted Agents in the Treatment of Indolent B-Cell Non-Hodgkin LymphomasAdrian Minson, Constantine Tam, Michael Dickinson, et al.Cancer Nursing|November 27, 2024
Preparing Nurses for CD20-CD3 Bispecific Antibody Treatment in Patients With Non-Hodgkin Lymphoma: A Scoping Review of Adverse Events and Management Strategies From Early Phase and Pivotal TrialsSam van der Linde, Emily Knights, Molly Robertson, et al.Pathology|March 9, 2021
CAR-T cell therapy: practical guide to routine laboratory monitoringAdrian G Selim, Adrian Minson, Piers Blombery, et al.British Journal of Haematology|March 20, 2025
Enterocolitis associated with glofitamab-First report and clinicopathological findings in three casesSean McKeague, Molly Robertson, Sam van der Linde, et al.Clinical & Translational Immunology|August 2, 2021
Dilemmas in the diagnosis and pathogenesis of atypical late-onset familial haemophagocytic lymphohistiocytosisAdrian Minson, Ilia Voskoboinik, Andrew GriggThe Lancet. Haematology|February 1, 2023
Treatment approaches for patients with TP53-mutated mantle cell lymphomaThomas E Lew, Adrian Minson, Michael Dickinson, et al.Leukemia & Lymphoma|April 21, 2026
Impact of peri-transplant consolidative radiotherapy in patients with relapsed or refractory classical Hodgkin lymphomaBelinda A Campbell, Adrian Minson, Rachel J Brown, et al.British Journal of Haematology|May 9, 2024
Relapse after glofitamab has a poor prognosis and rates of CD20 loss are highSamuel Grigg, Adrian Minson, Elizabeth Prins, et al.Pageof 15